AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

[cafead]

via AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses at week 14, with 69% of patients achieving low disease activity.

article source